A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Phase 2CompletedNCT02055820

Hoffmann-La Roche267 enrolled

Overview

This is a multicenter, open-label, dose-finding study of venetoclax administered orally in combination with rituximab (R) or obinutuzumab (G) and standard doses of cyclophosphamide, doxorubicin, vincristine and oral prednisone (CHOP) in participants with Non-Hodgkin's Lymphoma (NHL). The study consisted of 2 stages: a dose-finding Phase Ib stage and a Phase II expansion stage. In the Phase I portion of the study, participants were randomized to one of 2 treatment arms venetoclax in combination with R-CHOP (Arm A) and venetoclax in combination with G-CHOP (Arm B) and explored the doses of venetoclax in combination with R-CHOP and G-CHOP. The maximum tolerated dose (MTD) of venetoclax in combination with R-CHOP and G-CHOP was determined during the dose-finding stage. For the Phase II portion of the study, the venetoclax dose for venetoclax + R-CHOP was on a non-continuous dosing schedule as determined by the Phase Ib portion of the study based on safety and tolerability observed in participants treated in the dose escalation portion of the study. On 17 July 2016, Roche/Genentech as the sponsor of Study BO21005 (Goya study), a Phase III study that evaluated G CHOP versus R-CHOP in 1L DLBCL, informed through a press release that the primary endpoint of investigator-assessed PFS was not met. Given these results, Arm B (venetoclax + G-CHOP) was not expanded in Phase II in patients who are first-line with DLBCL.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

267

Conditions

Lymphoma, Non-Hodgkin

Interventions

VenetoclaxDRUG

Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) on Days 4-10 of Cycle 1 and Days 1-10 of Cycles 2-8 during Phase I and MTD will be administered according to the same schedule during Phase II.

CyclophosphamideDRUG

Cyclophosphamide 750 milligrams per square meter (mg/m\^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.

ObinutuzumabDRUG

Obinutuzumab will be administered by IV infusion as an absolute dose of 1000 mg on Days 1, 8, 15 of Cycle 1 and Day 1 of Cycles 2-8 (cycle length = 21 days).

RituximabDRUG

Rituximab 375 mg/m\^2 dose will be administered IV on Day 1 of every 21-day cycle.

DoxorubicinDRUG

Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.

VincristineDRUG

Vincristine 1.4 mg/m\^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.

PrednisoneDRUG

Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: General Inclusion Criteria: * At least one bi-dimensionally measurable lymphoma lesion on CT scan defined as \> 1.5 cm in its longest dimension, which is also FDG avid by screening PET scan. * Confirmed availability of archival or freshly biopsied tumor tissue prior to study enrollment * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 * Adequate hematologic function * For female participants of childbearing potential, agreement to use highly effective forms of contraception Dose-Escalation Portion of the Study: * Participants must have histologically confirmed B-cell NHL, except MCL or SLL * Participants must have never received previous R-CHOP treatment * Any relapsed/refractory participants that are enrolled during the dose escalation should have received only a single previous treatment regimen Expansion Portion of the Study: * Participants must have previously untreated CD20-positive DLBCL and IPI score must be 2-5 Exclusion Criteria: General Exclusion Criteria: * History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products * Contraindication to receive any of the individual components of CHOP, rituximab or obinutuzumab * Prior anthracycline therapy * Participants with ongoing corticosteroid use \>30 mg per day of prednisone or equivalent * CNS lymphoma or primary mediastinal DLBCL * Vaccination with live vaccines within 28 days prior to randomization * Chemotherapy or other investigational therapy within 28 days prior to the start of Cycle 1 * History of other malignancy that could affect compliance with the protocol or interpretation of results * Evidence of significant, uncontrolled concomitant disease * Significant cardiovascular disease or significant pulmonary disease * Left ventricular ejection fraction less than (\<) 50% as defined by multiple-gated acquisition (MUGA) * Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day 1 * Received the following agents within 7 days prior to the first dose of venetoclax: steroid therapy for anti-neoplastic intent; strong and moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers; grapefruit/grapefruit products, seville oranges or star fruit within 3 days prior to the first dose of venetoclax * Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis * Recent major surgery * Women who are pregnant or lactating Dose-Escalation Portion of the Study: * Participants with confirmed mantle cell lymphoma (MCL) or small lymphocytic lymphoma (SLL) Expansion Portion of the Study: * Participants with transformed lymphoma (participants with discordant bone marrow involvement (i.e., low grade histology in bone marrow) may be considered after discussion with the Medical Monitor) * Prior therapy for NHL

Locations (52)

St. Jude Heritage Healthcare

Fullerton, California, United States

UCLA Jonsson Comprehensive Cancer Center

Los Angeles, California, United States

Central Coast Medical Oncology

Santa Maria, California, United States

The West Clinici

St Louis, Missouri, United States

Hackensack University Medical Center; WFAN - Imus Pediatric Center

Hackensack, New Jersey, United States

Outcomes

Primary Outcomes

Safety: Number of Participants With Dose-Limiting Toxicities (DLTs)

DLTs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Decrease in B cells, lymphopenia, and leukopenia caused by lymphopenia were not considered DLTs but instead were expected outcomes of study treatment. Any Grade \>/= 3 adverse event, that was attributed to having a reasonable possibility of being related to the combined administration of venetoclax plus R-CHOP or G-CHOP, that could not be attributed by the investigator to an alternative, clearly identifiable cause such as tumor progression, concurrent illness or medical condition, or concomitant medication and that occurred during the DLT observation period (start of venetoclax treatment through end of Cycle 2) was considered a DLT for dose-escalation purposes. Grade 3 or 4 neutropenia or thrombocytopenia identified on Day 1 of Cycle 2 or 3, resulting in dose delay were considered DLTs.

Time frame: Start of venetoclax administration (Cycle 1 Day 4 or 3 days after first CHOP dose) up to end of Cycle 2 (cycle length = 21 days)

Percentage of Previously Untreated DLBCL Participants With Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Scan Using the Modified Lugano Classification Assessed by Independent Review Committee (IRC)

CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake \</= mediastinum; 3) uptake \< mediastinum but \</= liver. No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy

Time frame: Baseline up to end of treatment (up to approximately 6 months)

Percentage of Participants With CR Defined by PET/CT Scan in Previously Untreated DLBCL Co-Expressing Both Bcl-2 and c-Myc Proteins (DE-DLBCL) Participants Assessed by IRC

Time frame: Baseline up to end of treatment (up to approximately 6 months)

Secondary Outcomes

Venetoclax Plasma PK: Area Under the Plasma Concentration-Time Curve (AUC)

AUC was calculated based on measurement of venetoclax concentration in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. Data are reported as hour\*micrograms per milliliter (hr\*mcg/mL)

Time frame: Predose (within 30 minutes) & 2, 4, 6, 8 hours (Hr) postdose on Cycle 1 Day 4 (cycle length = 21 days)

Venetoclax Plasma PK: Time to Maximum Observed Plasma Concentration (Tmax)

Tmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.

Time frame: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)

Venetoclax Plasma PK: Maximum Observed Plasma Concentration (Cmax)

Cmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. Data are reported as micrograms per milliliter

Time frame: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)

Venetoclax Plasma PK: Minimum Plasma Concentration (Cmin) Within the Dosing Interval

Cmin was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.

Time frame: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)

Prednisone Plasma PK: AUC

AUC was determined based on measurement of Predisone concentrations in plasma over time.

Time frame: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)

Prednisone Plasma PK: Tmax

Tmax was determined based on measurement of Predisone concentrations in plasma over time.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

San Juan Oncology Associates

Farmington, New Mexico, United States

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Uni of Rochester Medical Center; Wilmot Cancer Center, Pharmacy Department

Rochester, New York, United States

Tennessee Oncology

Nashville, Tennessee, United States

Concord Repatriation General Hospital

Concord, New South Wales, Australia

...and 42 more locations

Time frame: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)

Prednisone Plasma PK: Cmax

Cmax was determined based on measurement of Predisone concentrations in plasma over time.

Time frame: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)

Rituximab PK: Cmax

Cmax was determined using the post-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1.